Humana (NYSE:HUM) Price Target Raised to $316.00

Humana (NYSE:HUM) had its target price raised by investment analysts at JPMorgan Chase & Co. from $214.00 to $316.00 in a research report issued on Monday,MarketScreener reports. The brokerage currently has a “neutral” rating on the insurance provider’s stock. JPMorgan Chase & Co.‘s target price indicates a potential downside of 9.20% from the company’s current price.

Other research analysts also recently issued research reports about the stock. Barclays boosted their target price on shares of Humana from $180.00 to $344.00 and gave the company an “equal weight” rating in a research note on Tuesday, May 26th. Guggenheim lifted their price target on shares of Humana from $252.00 to $269.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Piper Sandler reissued a “neutral” rating and issued a $254.00 price objective (up from $182.00) on shares of Humana in a research report on Wednesday, May 13th. The Goldman Sachs Group raised their target price on shares of Humana from $158.00 to $195.00 and gave the stock a “sell” rating in a research report on Thursday, April 30th. Finally, Wells Fargo & Company downgraded Humana from a “cautious” rating to a “reduce” rating in a report on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, fourteen have issued a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat, Humana currently has an average rating of “Hold” and a consensus price target of $286.13.

Humana Price Performance

Shares of HUM stock traded down $2.06 during trading hours on Monday, hitting $348.02. The company’s stock had a trading volume of 94,739 shares, compared to its average volume of 1,902,144. The company has a current ratio of 1.77, a quick ratio of 1.77 and a debt-to-equity ratio of 0.66. The business has a fifty day moving average of $248.43 and a 200-day moving average of $232.39. Humana has a twelve month low of $163.11 and a twelve month high of $351.88. The stock has a market cap of $41.78 billion, a price-to-earnings ratio of 37.18, a P/E/G ratio of 2.00 and a beta of 0.76.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.97 by $0.34. The firm had revenue of $39.65 billion for the quarter, compared to analyst estimates of $39.37 billion. Humana had a return on equity of 10.45% and a net margin of 0.82%.Humana’s revenue was up 23.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $11.58 EPS. Humana has set its FY 2026 guidance at 9.000- EPS. As a group, equities research analysts anticipate that Humana will post 9 EPS for the current year.

Institutional Trading of Humana

Institutional investors have recently modified their holdings of the company. Montag A & Associates Inc. raised its holdings in Humana by 1,880.0% in the fourth quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock valued at $25,000 after buying an additional 94 shares during the period. CoreCap Advisors LLC grew its stake in Humana by 54.4% during the fourth quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after buying an additional 37 shares during the period. Fideuram Asset Management Ireland dac acquired a new stake in shares of Humana in the fourth quarter worth $27,000. Reflection Asset Management acquired a new stake in shares of Humana in the fourth quarter worth $29,000. Finally, Rosenberg Matthew Hamilton raised its stake in shares of Humana by 136.0% in the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock valued at $30,000 after acquiring an additional 68 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.